Cargando…
The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study)
Background: Severe cases of lymphopenia have been reported during siponimod clinical trials, which may negatively impact its benefit/risk profile. Objective: We aimed to evaluate the incidence of lymphopenia following the initiation of siponimod treatment in clinical practice. The secondary objectiv...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607533/ https://www.ncbi.nlm.nih.gov/pubmed/37892611 http://dx.doi.org/10.3390/jcm12206471 |
_version_ | 1785127564194349056 |
---|---|
author | Sancho-López, Arantxa Ruiz-Antorán, Belén Iglesias Hernangómez, Teresa Ramírez-García, Almudena Gómez-Estévez, Irene Sanabria-Cabrera, Judith Llop Rius, Roser Pedrós, Consuelo Campodonico, Diana Jiménez-Jorge, Silvia García Luque, Amelia Costa Frossad França, Lucienne Montané, Eva Aldea-Perona, Ana Téllez Lara, Nieves Bosch Ferrer, Montserrat Rodriguez Jiménez, Consuelo Bonilla-Toyos, Elvira Sabín Muñoz, Julia Avendaño-Solá, Cristina Blasco Quilez, María Rosario |
author_facet | Sancho-López, Arantxa Ruiz-Antorán, Belén Iglesias Hernangómez, Teresa Ramírez-García, Almudena Gómez-Estévez, Irene Sanabria-Cabrera, Judith Llop Rius, Roser Pedrós, Consuelo Campodonico, Diana Jiménez-Jorge, Silvia García Luque, Amelia Costa Frossad França, Lucienne Montané, Eva Aldea-Perona, Ana Téllez Lara, Nieves Bosch Ferrer, Montserrat Rodriguez Jiménez, Consuelo Bonilla-Toyos, Elvira Sabín Muñoz, Julia Avendaño-Solá, Cristina Blasco Quilez, María Rosario |
author_sort | Sancho-López, Arantxa |
collection | PubMed |
description | Background: Severe cases of lymphopenia have been reported during siponimod clinical trials, which may negatively impact its benefit/risk profile. Objective: We aimed to evaluate the incidence of lymphopenia following the initiation of siponimod treatment in clinical practice. The secondary objectives included the analysis of factors predisposing to and the clinical relevance of lymphopenia events. Methods: In this multicenter retrospective cohort study, information collected from the medical records of 129 patients with MS from 15 tertiary hospitals in Spain who initiated treatment with Siponimod were followed-up for at least 3 months, including at least one lymphocyte count evaluation per patient. Results: Of the 129 patients, 121 (93.6%) reported lymphopenia events, including 110 (85.3%) with grade ≤ 3 and 11 (8.5%) with grade 4 lymphopenia, higher than those reported in the pivotal clinical trial (73.3% and 3.3% for grade ≤ 3 and grade 4 lymphopenia, respectively). The study included an unexpectedly high proportion of male subjects (72.9%), which might have led to an underestimation of the actual magnitude of the risk. Conclusions: In this study, the incidence and severity of lymphopenia after starting siponimod treatment were higher than those reported in previous clinical trials. Therefore, our results reinforce the need for the closer monitoring of novel MS drugs in clinical practice, as well as larger and longer follow-up studies to properly characterize this risk. |
format | Online Article Text |
id | pubmed-10607533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106075332023-10-28 The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) Sancho-López, Arantxa Ruiz-Antorán, Belén Iglesias Hernangómez, Teresa Ramírez-García, Almudena Gómez-Estévez, Irene Sanabria-Cabrera, Judith Llop Rius, Roser Pedrós, Consuelo Campodonico, Diana Jiménez-Jorge, Silvia García Luque, Amelia Costa Frossad França, Lucienne Montané, Eva Aldea-Perona, Ana Téllez Lara, Nieves Bosch Ferrer, Montserrat Rodriguez Jiménez, Consuelo Bonilla-Toyos, Elvira Sabín Muñoz, Julia Avendaño-Solá, Cristina Blasco Quilez, María Rosario J Clin Med Article Background: Severe cases of lymphopenia have been reported during siponimod clinical trials, which may negatively impact its benefit/risk profile. Objective: We aimed to evaluate the incidence of lymphopenia following the initiation of siponimod treatment in clinical practice. The secondary objectives included the analysis of factors predisposing to and the clinical relevance of lymphopenia events. Methods: In this multicenter retrospective cohort study, information collected from the medical records of 129 patients with MS from 15 tertiary hospitals in Spain who initiated treatment with Siponimod were followed-up for at least 3 months, including at least one lymphocyte count evaluation per patient. Results: Of the 129 patients, 121 (93.6%) reported lymphopenia events, including 110 (85.3%) with grade ≤ 3 and 11 (8.5%) with grade 4 lymphopenia, higher than those reported in the pivotal clinical trial (73.3% and 3.3% for grade ≤ 3 and grade 4 lymphopenia, respectively). The study included an unexpectedly high proportion of male subjects (72.9%), which might have led to an underestimation of the actual magnitude of the risk. Conclusions: In this study, the incidence and severity of lymphopenia after starting siponimod treatment were higher than those reported in previous clinical trials. Therefore, our results reinforce the need for the closer monitoring of novel MS drugs in clinical practice, as well as larger and longer follow-up studies to properly characterize this risk. MDPI 2023-10-11 /pmc/articles/PMC10607533/ /pubmed/37892611 http://dx.doi.org/10.3390/jcm12206471 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sancho-López, Arantxa Ruiz-Antorán, Belén Iglesias Hernangómez, Teresa Ramírez-García, Almudena Gómez-Estévez, Irene Sanabria-Cabrera, Judith Llop Rius, Roser Pedrós, Consuelo Campodonico, Diana Jiménez-Jorge, Silvia García Luque, Amelia Costa Frossad França, Lucienne Montané, Eva Aldea-Perona, Ana Téllez Lara, Nieves Bosch Ferrer, Montserrat Rodriguez Jiménez, Consuelo Bonilla-Toyos, Elvira Sabín Muñoz, Julia Avendaño-Solá, Cristina Blasco Quilez, María Rosario The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) |
title | The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) |
title_full | The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) |
title_fullStr | The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) |
title_full_unstemmed | The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) |
title_short | The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study) |
title_sort | need for the closer monitoring of novel drugs in ms: a siponimod retrospective cohort study (realhes study) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607533/ https://www.ncbi.nlm.nih.gov/pubmed/37892611 http://dx.doi.org/10.3390/jcm12206471 |
work_keys_str_mv | AT sancholopezarantxa theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT ruizantoranbelen theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT iglesiashernangomezteresa theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT ramirezgarciaalmudena theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT gomezestevezirene theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT sanabriacabrerajudith theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT llopriusroser theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT pedrosconsuelo theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT campodonicodiana theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT jimenezjorgesilvia theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT garcialuqueamelia theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT costafrossadfrancalucienne theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT montaneeva theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT aldeaperonaana theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT tellezlaranieves theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT boschferrermontserrat theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT rodriguezjimenezconsuelo theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT bonillatoyoselvira theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT sabinmunozjulia theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT avendanosolacristina theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT blascoquilezmariarosario theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT theneedfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT sancholopezarantxa needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT ruizantoranbelen needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT iglesiashernangomezteresa needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT ramirezgarciaalmudena needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT gomezestevezirene needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT sanabriacabrerajudith needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT llopriusroser needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT pedrosconsuelo needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT campodonicodiana needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT jimenezjorgesilvia needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT garcialuqueamelia needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT costafrossadfrancalucienne needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT montaneeva needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT aldeaperonaana needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT tellezlaranieves needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT boschferrermontserrat needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT rodriguezjimenezconsuelo needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT bonillatoyoselvira needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT sabinmunozjulia needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT avendanosolacristina needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT blascoquilezmariarosario needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy AT needfortheclosermonitoringofnoveldrugsinmsasiponimodretrospectivecohortstudyrealhesstudy |